Glycopolymer and Poly(β-amino ester)-Based Amphiphilic Block Copolymer as a Drug Carrier

Elif L. Sahkulubey Kahveci, Muhammet U. Kahveci,* Asuman Celebi, Timucin Avsar, and Serap Derman*

ABSTRACT: Glycopolymers are synthetic macromolecules having pendant sugar moieties and widely utilized to target cancer cells. They are usually considered as a hydrophilic segment of amphiphilic block copolymers to fabricate micelles as drug carriers. A novel amphiphilic block copolymer, namely, poly(2-deoxy-2-methacrylamido-D-glucose-co-2-hydroxyethyl methacrylate)-b-poly(β-amino ester) [P(MAG-co-HEMA)-b-PBAE], with active cancer cell targeting potential and pH responsivity was prepared. Tetrazine end functional P(MAG-co-HEMA) and norbornene end functional PBAE blocks were separately synthesized through reversible addition fragmentation chain transfer polymerization and Michael addition-based poly-condensation, respectively, and followed by end-group transformation. Then, inverse electron demand Diels Alder reaction between the tetrazine and the norbornene groups was performed by simply mixing to obtain the amphiphilic block copolymer. After characterization of the block copolymer in terms of chemical structure, pH responsivity, and drug loading/releasing, pH-responsive micelles were obtained with or without doxorubicin (DOX), a model anticancer drug. The micelles exhibited a sharp protonated/deprotonated transition on tertiary amine groups around pH 6.75 and the pH-specific release of DOX below this value. Eventually, the drug delivery potential was evaluated by cytotoxicity assays on both the noncancerous human umbilical vein endothelial cell (HUVEC) cell line and glioblastoma cell line, U87-MG. While the DOX-loaded polymeric micelles were not toxic in noncancerous HUVEC cells, being toxic only to the cancer cells indicates that it is a potential specific cell targeting strategy in the treatment of cancer.

INTRODUCTION

Advanced drug delivery systems are described as integrated materials or devices to deliver therapeutic agents in a site-directed fashion and/or to tune release kinetics. They offer many advantages including enhanced drug stability and solubility, facilitated passage across biological barriers, prolonged circulation times leading to improved bioavailability, efficacy, and safety. In addition, these systems allow targeted delivery resulting in the accumulation of therapeutics at the diseased area, and also controlled kinetics of the release. Therefore, advanced drug delivery systems have been recently considered as an important element of treatment of diseases in terms of maximizing efficacy of therapeutics and minimizing their side effects. In recent years, tremendous efforts have been focused on the development of drug delivery systems for many diseases, especially cancer. Stimuli responsive polymeric micelles as drug delivery systems have been used for the controlled release of drugs into the action of site only in response to environmental or physical stimuli, such as low pH, temperature, enzyme, sound, redox, or light. pH-sensitive polymers provide a specific opportunity for the targeted treatment of cancer, since the increased glucose metabolism of cancer cells causes accumulation of H\(^+\) ions and, as a result, lowers the pH in the tumor microenvironment ranging from 5.7 to 7.8. Furthermore, subcellular compartments such as lysosomes have much lower pH, 5.0–5.5. As normal tissues have a pH of 7.4, the pH difference between normal tissues and tumor tissue/lysosome has allowed the development of several pH-sensitive polymeric drug delivery materials for cancer treatment.

Poly(β-amino ester) (PBAE) is one of the pH-responsive polymers containing tertiary amine groups with a pK\(_a\) value around 6.5. As pH decreases below the pK\(_a\), the tertiary amines are protonated, and the polymer becomes a cationic polymer with high solubility in aqueous solutions. This cationic polymer can readily react with negatively charged molecules such as DNA and RNA and form a complex called polyplex. 

Received: September 2, 2022
Revised: October 20, 2022
Published: November 1, 2022
Therefore, PBAEs have been widely utilized in gene delivery since they were introduced as nontoxic and biodegradable DNA vectors by Langer and co-workers in 2000.21-23 Because of the protonation and deprotonation of the tertiary amine group, PBAEs have been considered as promising pH-sensitive drug delivery materials for tumor targeting.4,41-47 For instance, several PBAEs in combination with poly(ethylene glycol) (PEG) as the hydrophilic segment have been utilized as drug carriers in the form of hydrogels.26,29 micelles,10-33 blends,34,35 etc. Even, PBAE-based nanoparticles were developed for the co-delivery of anticancer chemotherapeutics (i.e., doxorubicin (DOX)) and a RNA molecule or proapoptotic peptide to develop a system to treat drug resistant cancer more efficiently.36 In another study, D-/ε-tocopheryl PEG succinate incorporated PBAE was fabricated for overcoming multidrug resistance.1 Therefore, PBAE is an elegant candidate to develop a pH-responsive drug carrier with different properties.

In addition to variation in pH, another important difference of the cancer cells is the overexpression of various membrane proteins such as growth factor receptors (e.g., epidermal growth factor receptors), hormone receptors, transferrin receptors,38 folate receptors,39 lectins,40 and glucose transporters,41 (GLUTs) which are responsible in growth, differentiation, and high metabolism of the cancer cells. Therefore, these receptors are widely employed in diagnostic tools and drug delivery systems that specifically target cancer cells.42,43 One of these overexpressed proteins is GLUTs that take up glucose more effectively, because cancer cells consume a much higher amount of sugar compared to healthy cells.41,44 In addition, a polysaccharide binding membrane glycoprotein involved in several cell–cell interactions, namely, CD44, is overexpressed in tumor cells. Therefore, using sugar moieties as ligands of either GLUTs or CD44 to actively target cancer cells is becoming one of the important strategies in cancer therapy.45-47 Glycopolymers are synthetic macromolecules having pendant sugar moieties and widely used to target cancer cells.36,48-50 They are usually utilized as the hydrophilic segment of amphiphilic block copolymers to fabricate micelles as drug carriers.51,52 One of these glycopolymers is poly(2-deoxy-2-methacrylamido-α-D-glucose) (PMAG) mostly obtained by reversible addition fragmentation chain transfer (RAFT) polymerization and has been extensively studied in delivery applications. Since PMAG is hydrophilic, it is usually combined with hydrophobic segments including poly(L-lysine-co-L-phenylalanine),53 poly[N-(2-aminooethoxy)methacrylamide],54 poly[N-[3-(N,N-dimethylamino) propyl] methacrylamide],55 and poly(O-cholesteryl methacrylate)66 to fabricate core–shell micelles. Such polymeric micelles are useful in both passive targeting due to their sizes (enhanced permeation and retention effect)57 and active targeting via glucose groups60 leading to decreased systemic toxicity and side effects.

To the best of our knowledge, glycopolymers and PBAE-based block copolymers have not been reported; thus, a novel pH-responsive amphiphilic block copolymer, namely, PMAG-co-2-hydroxyethyl methacrylate)-b-PBAE [P(MAG-co-HEMA)-b-PBAE], with active cancer cell targeting potential was synthesized for the first time. Tetrazine end functional P(MAG-co-HEMA) and norbornene end functional PBAE blocks were individually synthesized through RAFT polymerization and Michael addition type poly-condensation, respectively, and subsequent end-group transformations. Then, the amphiphilic block copolymer was obtained through an inverse electron demand Diels Alder (IEDDA) reaction between the tetrazine and the norbornene groups by simply mixing. After characterization of the block copolymer, pH responsivity and drug loading/releasing of the micellar structures produced from the block copolymer were evaluated with DOX as a model anticancer drug. Eventually, anticancer drug delivery potential was examined via cell viability assays for both the noncancerous human umbilical vein endothelial cell (HUVEC) cell line and glioblastoma cell line U87-MG.

### EXPERIMENTAL SECTION

**Materials.** 1,4-Butanediol diacrylate (BDA) (90%, Sigma Aldrich), 5-amino-1-pentanol (AP) (95%, Sigma Aldrich), S-norbornene-2-methyamine (mixture of isomers, TCI), N- (+)-glucosamine hydrochloride (Sigma Aldrich), methacryloyl chloride (97%, Sigma Aldrich), contains 200 ppm monomethyl ether hydroquinone as a stabilizer), potassium carbonate (Alfa Aesar), HEMA (Sigma Aldrich), 4-cyano-4-[(dodecysulfanilylthiocarbonyl)sulfanyl]pentanoic acid (97%, HPLC, Sigma Aldrich), azobisobutyronitrile (AIBN) (98%, Sigma Aldrich), N-(3-dimethylaminopropyl)-N'-ethylcarbamidomethyl hydrochloride (EDC) (Sigma Aldrich), N-hydroxysuccinimide (NHS) (Merck), triethyl amine (Et3N) (Sigma Aldrich), and all other chemicals were of analytical grade, obtained from commercial suppliers, and used without further purification unless otherwise specified. Tetrazine amine (Tz-NH2) was synthesized according to our previous study.58 **Characterization.** An Agilent nuclear magnetic resonance (NMR) System VNMR S 500 Spectrometer was used for the 1H NMR analysis at room temperature in deuterated solvents with Si(CH3)4 as an internal standard. UV–vis analyses were performed on a Peak Instruments C-7000UV spectrophotometer with 1-cm path length cuvette, respectively. The molecular masses of the polymers were determined by two distinct gel permeation chromatography (GPC) systems using tetrahydrofuran (THF) and N,N-dimethyl formamide (DMF) as the eluent. In the first one, THF was utilized as the eluent at a flow rate of 1.0 mL min−1 at 40 °C on a Tosoh EcoSEC GPC system equipped with an autosampler system, a temperature controlled pump, a column oven, a refractive index (RI) detector, a purge and degasser unit, TSK gel superf2000, and a 4.6 mm ID × 15 cm × 2 cm column. The RI detector was calibrated with polystyrene and poly(methyl methacrylate) standards and GPC data were analyzed using EcoSEC Analysis software. A Tosoh EcoSEC dual detection (RI and UV) GPC system coupled to an external Wyatt Technologies Dawn Heleos-II multilayer light scattering detector and a Wyatt Technologies DynaPro NanoStar DLS detector was also used for size exclusion chromatography (SEC) measurements. DMF was used as the eluent at a flow rate of 1.0 mL min−1 at 45 °C. The column set was one Tosoh TSKgel G5000HHR column (7.8 × 300 mm), one Tosoh TSKgel G3000HHR column (7.8 × 300 mm), one Tosoh TSKgel SuperH-RC reference column for EcoSEC, and one Tosoh TSKgel HHR-H guard column (6 × 40 mm). Absolute molecular weights and molecular weight distributions were calculated using the Astra 7.1.2 software package.

**Synthesis of PBAE Diacrylate.** Bis-acrylate functional PBAE was synthesized by aza-Michael addition-based poly-condensation polymerization.59 In brief, BDA (1.64 mL, 8.68 mmol) was taken into an ovoidial and AP (0.89 g, 8.68 mmol) was added. The reaction mixture was placed in a preheated oil bath at 100 °C with stirring. After 24 h, excess BDA (0.33 mL, 1.74 mmol) was added into the vial to obtain acrylate end-capped PBAEs. After 3 h of further stirring at 100 °C, the reaction was cooled down to room temperature. The obtained polymer was dissolved in dichloromethane and precipitated in cold diethyl ether twice for the removal of residual monomers and oligomers. Then, the PBAE diacrylate was dried for 24 h at 40 °C under vacuum and stored at −20 °C until use. (Mw/Mn: 7300 g/mol; Mw/MnGPC: 2.08; Mw/NMR: 1830 g/mol; yield: 50%).

**1H NMR (500 MHz, CDCl3, δ):** 1.29–1.38 (br, m, N CH3,CH2CH2CH2CH2OH), 1.43–1.48 (br, m, N CH3,CH2CH2CH2CH2OH), 1.53–1.58 (br, m,
NCH₂CH(CH₂)₂CH₂OH), 1.68–1.77 (br, NCH₂), 2.85–2.87 (br, CH₂), 2.98–3.01 (br, CH₂), 3.14–3.17 (br, CH₂), 3.45–3.48 (br, CH₂), 3.58–3.64 (br, NCH), 5.54 (1H, dd, CH=CH=CH₂), 5.67 (1H, dd, CH=CH=CH₂), 5.82–5.85 (br, CH₂), 6.11 (1H, d, CH=CH₂), 6.40 (2H, d, polymer-CH₂ = CH₂H₂).

End-group Transformation of PBAE Diacrylate to Norbornene. PBAE diacrylate (1.21 g, Mᵢ,GPC: 7300 g/mol, 0.166 mmol) was dissolved in THF (5 mL). After the addition of 5-norbornene-2-methyl amine (NB-NH₂) (215 µL, 1.68 mmol), the reaction solution was stirred at room temperature for 24 h. The modified polymer was precipitated in diethyl ether twice. After being dried under vacuum for 24 h, the norbornene functional PBAE (NB-PBAE-NB) was obtained.

Synthesis of 2-Deoxy-2-methacrylamido-α-glucose. 2-Deoxy-2-methacrylamido-α-glucose (MAG) was synthesized according to a published procedure. Briefly, D-(+)-glucosamine hydrochloride (10.0 g, 46 mmol) was dissolved in minimal amount of DMSO containing potassium carbonate 6.41 g (46 mmol) in a 500-mL single-neck round-bottom flask with vigorous stirring, then the mixture was cooled down to −10 °C with an acetone/ice bath. Afterward, methacryloyl chloride (4.0 mL, 41 mmol) was added dropwise into the mixture, and the mixture was stirred at −10 °C for 30 min. After another stirring for 3 h at room temperature, the precipitated white salt was filtered off from the crude product using a sintered funnel with vacuum suction. A white slurry was obtained after concentration of the filtrate on a rotary evaporator. The product was purified by a column chromatography using dichloromethane/methanol (4:1) as the eluent. Yield: 37%.

1H NMR (500 MHz, CDCl₃, δ): 2.00 (3H, s, CH₃), 3.54 (1H, dd, CH=CH=CH₂), 3.56 (1H, dd, CH=CH=CH₂), 3.50–3.58 (m, 5-Hp, 4-Hp₂), 3.65–3.71 (m, 3-Hp), 3.78–3.98 (m, 2-Hp, 3-Hp, 6-Hp₂), 4.00 (5-Hp), 4.02 (dd, 2-Hp), 4.84 (dd, 1-Hp), 5.29 (d, 1-Hp).

Synthesis of P(MAG-co-HEMA) by RAFT Polymerization. Poly(2-deoxy-2-methacrylamido-α-glucose-co-2-hydroxyethyl methacrylate) [P(MAG-co-HEMA)] was synthesized via RAFT polymerization with a molar ratio of reagents [MAG]:[RAFT] ([CTA]): [AIBN] = 12:12:1.0:25. MAG (923 mg, 3.73 mmol), 2-HEMA (486 mg, 3.73 mmol), 2,2′-AIBN (12.8 mg, 0.079 mmol), and 4-cyan-4-((dodecyiltrifluoromethyl)carbonyl)sulfonyl) pentanoic acid (CTA) (126 mg, 0.31 mmol) were dissolved with DMF (9 mL), respectively, in a Schlenk tube equipped with a magnetic stir bar. The polymerization solution was degassed via three freeze-pump-thaw cycles, refilled with nitrogen, and then stirred in an oil bath at 70 °C for about 18 h. After 18 h, the flask was cooled and the solution was poured into a 20 times excess of THF. The precipitate was filtered off and dried under vacuum. The monomer conversion was gravimetrically determined as 88%. To remove unreacted monomer and other impurities, the polymer was dialyzed against distilled water using dialysis membrane with a molecular weight cutoff (MWCO) of 3500 Da. Then, the solution was lyophilized to yield P(MAG-co-HEMA) as white powder. (Mᵢ,GPC: 10,950 g/mol, Mₙ,GPC: 10,021 g/mol, Mₘ,n: 4900 g/mol; yield: 88%).

End-Group Transformation of P(MAG-co-HEMA) to Tetrazine. Carboxylic acid end of P(MAG-co-HEMA) was activated via EDC and NHS, and reacted with amino tetrabenez (Tz-NH₂). Briefly, P(MAG-co-HEMA) (1.0 g, 9.1 × 10⁻⁵ mol) was dissolved in 10 mL of dimethyl sulfoxide (DMSO) and the carboxylic acid group was activated using EDC (98 mg, 5.1 × 10⁻⁴ mol) in the presence of NHS (35 mg, 3.0 × 10⁻⁷ mol) and triethyl amine (Et₃N) (43 µL, 3.1 × 10⁻⁴ mol). The reaction mixture was stirred at 25 °C for 24 h. Afterward, Tz-NH₂ (155 mg, 7.7 × 10⁻⁴ mol) dissolved in DMSO was added dropwise to the reaction mixture. After 24 h of stirring, the reaction mixture was precipitated and washed twice with THF. Then, the pink polymer (P(MAG-co-HEMA)-Tz) was dried overnight at 40 °C under vacuum and stored at −20 °C until use.

Synthesis of P(MAG-co-2-HEMA)-b-PBAE) [P(MAG-co-HEMA)-b-PBAE]. The block copolymer was prepared via the IEDDA click reaction. The norbornene functional PBAE (NP-PBAE-NB) (445 mg, 5.9 × 10⁻³ mol) was dissolved in 3 mL of DMSO in a vial equipped with a magnetic stirrer. The tetrazene functional P(MAG-co-HEMA)-Tz (618 mg, 5.6 × 10⁻³ mol) was added into this solution in two portions (75% + 25% by mass) to follow the reaction with UV−vis spectroscopy. At specific time intervals, the UV−vis spectra were recorded. After the completion of reaction (about 37 h), the reaction mixture was precipitated and washed twice with diethyl ether containing a small amount of ethanol. After being dried under vacuum for 24 h, the block copolymer [P(MAG-co-HEMA)-b-PBAE] was received. (Recovery: 63%).

pH-Sensitive Behavior of the Polymers. pH sensitivity of the norbornene functional PBAE and the block copolymer [P(MAG-co-HEMA)-b-PBAE] was evaluated by acid−base potentiometric titration and measurement of optical density (OD) of the solutions. For this, 6.4 mg of the copolymer was dispersed in 3 mL distilled water and the pH was adjusted to 3 by the addition of small aliquots of 0.1 M HCl. Then, the polymer solution was titrated by the addition of 0.1 M NaOH, and at each step, the pH and OD (at 550 nm) of the solution were measured by a pH-meter and UV−vis spectrophotometer, respectively. To determine the base dissociation constant (pKₐ), OD values and volumes of NaOH solutions were plotted against pH values.

Preparation of Blank Micelles. The micelles were obtained via consecutive acid and base addition to an aqueous dispersion of the block copolymer. Briefly, P(MAG-co-HEMA)-b-PBAE (8.3 mg) dissolved in minimal amount of DMSO was dispersed in 2.5 mL of distilled water, then 0.1 HCl was added under stirring to adjust pH 3. After the addition of the acid, the turbid mixture became clear, so that the polymer was dissolved completely. Then, 0.1 M NaOH solution (~0.5 mL) was slowly added in a dropwise manner under stirring till the pH was around 9. The solution became cloudy indicating the formation of micelles. The mixture was dialyzed against distilled water using a dialysis membrane with an MWCO of 3500 Da. In the end, the micelles were obtained.

Preparation of DOX-Loaded Micelles. DOX, which was chosen as a model drug, was encapsulated into the micelles using a similar method. A typical procedure for drug loading is as follows. First, 70 mg of the block copolymer and 7 mg of DOX hydrochloride dissolved in a minimal amount of DMSO (~600 µL) was added to 2.5 mL distilled water, and pH was adjusted to 3 by the addition of 0.1 M HCl. Then 0.1 M NaOH slowly added dropwise under stirring and pH was adjusted to 9 by the addition of 0.1 M NaOH. The solution was dialyzed against distilled water using a membrane (MWCO 3500 Da) for a day at room temperature. The water was replaced with fresh water six times. DOX-loaded red solid polymeric micelles were obtained after lyophilization.

The drug loading capacity (DLC) and drug loading efficiency (DLE) of the polymeric micelles were determined using eqs 1 and 2, respectively. In a representative example, 2.8 mg DOX-loaded micelles were solved in DMSO (8 mL); thus, the micelles were broken and the encapsulated DOX came out and was solubilized. Then, the absorbance at 483 nm was recorded by UV−vis spectroscopy. The DOX content of the micelle was determined by using a calibration curve established with absorbance values of DOX solutions of various concentrations at the same wavelength (483 nm).

\[
\text{DLC} \% = \frac{\text{mass of drug encapsulated in micelles}}{\text{mass of micelles containing drug}} \times 100\%
\]

(1)
Characterization of Micelles. Micelles (1 mg/mL) were dropped on a carbon film-coated Cu grid and left to dry overnight. Samples were imaged on a Thermo Scientific Quattro ESEM scanning electron microscope using a scanning transmission electron microscopy (STEM) detector under a high vacuum (30 kV) from a working distance of 7.7 mm, and the digital images of micelles were captured to analyze their morphology. Dynamic light scattering (DLS) (Malvern Zetasizer Nano ZS, Malvern Instruments, UK) was performed to determine the average size and size distribution, and electrophoretic light scattering was performed to determine the zeta potential of the prepared micelles. The critical micelle concentration (CMC) of the block copolymer with a variety of concentrations ranging from 10 mg/mL to $3 \times 10^{-6}$ mg/mL was measured by DLS. All DLS measurements were carried out at 25 °C and repeated three times. The CMC of the polymer was estimated by plotting count rate (kcps) as a function of concentration. The intersection of the upper and lower linear trend lines imply the CMC.\textsuperscript{64}

In Vitro Release of DOX from Polymeric Micelles. The release profiles of DOX from polymer micelles were studied using a dialysis method in 0.01 M phosphate buffered saline (PBS) at pH 7.4 and 5.3. In a typical drug release study, a solution (1 mL) of DOX-loaded polymeric micelles (1.5 or 1.9 mg/mL) in PBS (pH 7.4, 0.01 M) was dialyzed in a dialysis membrane (MWCO 3500 Da) against 30 mL of PBS (pH 7.4, 0.01 M or pH 5.3, 0.01 M) containing Tween 80 (1% or 0.33% w/v). At specific time intervals, 1 mL of buffer solution outside the dialysis membrane was withdrawn and replaced with an equal volume of fresh PBS buffer. The amount of DOX released from the micelles was determined by measuring absorbance at 483 nm using a UV–vis spectrophotometer. The cumulative release of DOX was calculated by using the following equation:\textsuperscript{65}

$$\text{DLE} \, (\%) = \frac{\text{mass of drug encapsulated in micelles}}{\text{mass of drug in feed}} \times 100\%$$

\text{(2)}
cumulative release (\%) 
\[= \frac{\text{mass of drug release at time of } t}{\text{total mass of drug in micelles taken in dialysis tube}} \times 100\%\]  

**Cell Viability Assay.** The HUVEC cell line and glioblastoma cell line U87-MG were used to evaluate the drug release performance of polymeric micelles by using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Micelles with DOX (EK255), without DOX (EK257), and only DOX groups were tested in triplicate. Drug concentrations ranging from 20 to 0.625 μg/mL were tested for 12, 24, and 48 h of treatment.

The protocol was summarized as follows: 10,000 cells were seeded into a sterile 96-well plate and incubated at 37 °C for 24 h in an incubator with 5% CO₂ and 95% humidity. Later, the medium was removed and the micelle containing cell media was added and incubated for 12, 24, and 48 h. Later, 10 μL of 5 mg/mL MTT solution was added to each well and incubated for 3 h at 37 °C. Finally, 100 μL of solubilization buffer was added to each well to dissolve the formazan crystals formed and additional 15 min of incubation was done at room temperature. After incubation, absorbance was measured at a wavelength of 570 nm in a Hitex Sense microplate reader. Percent cell viability scores were evaluated by normalizing the data to untreated cells on the corresponding day of incubation.

**Cellular Uptake Assay.** U87-MG cells were seeded on a 6-well plate (25 × 10⁴ cells/well) and incubated at 37 °C with 5% CO₂ for 24 h. Cells were subjected to DOX (5 μg/mL), DOX-loaded micelles (EK255) (final DOX concentration is 5 μg/mL), and free micelle groups (EK257) for 4 h. The cells were washed three times with 0.1% PBS-T. The cells were stained by 4′,6-diamidino-2-phenylindole (DAPI) for 2 min and washed three times with 0.1% PBS-T. Fluorescence imaging (Leica DM2500) was used to visualize and five different photographs of each group were taken. Excitation wavelengths were 320–380 nm for DAPI and 515–560 nm for DOX. Cellular uptake was analyzed by counting the DAPI and DOX containing cells on photographs. Percent cellular uptake was calculated as the ratio of all counted cells to cells with double positive staining (DAPI and DOX positive).

**Annexin V Staining.** APC Annexin V Apoptosis Detection Kit with propidium iodide (PI) (Biolegend, San Diego, USA) was used to determine cell death. Briefly, U87-MG cells were seeded on a 6-well plate at a density of 25 × 10⁴ cells per well and incubated at 37 °C with 5% CO₂ overnight. The cells were treated with 5 μg/mL of DOX, DOX-loaded micelle (EK255), and empty micelle (EK257) groups for 2 and 4 h. Cells were harvested and the pellets were resuspended in 100 μL of 1× Annexin V binding buffer. The cells were then incubated with 5 μL of Annexin V-FITC and 10 μL of PI for 15 min in the dark at room temperature and 400 μL of 1× Annexin V binding buffer was added, according to the manufacturer’s instructions. Cell fluorescence was measured by flow cytometry (NovoCyte, ACEA Biosciences Inc., CA, USA). The ratio of cell death was assessed with single PI positive cells (Q2−1). Early apoptosis and late apoptosis were detected by single APC positive cells (Q2−4) and APC and PI double positive (Q2−3) cells, respectively.

## RESULTS AND DISCUSSION

**Synthesis and Characterization of the Polymers.** P(MAG-co-HEMA)-b-PBAE was synthesized as shown in **Scheme 1** for the construction of pH-responsive, biodegradable micelles containing glucose moieties that potentially target specifically cancer cells. The IEDDA click reaction was chosen for the conjugation of the glycopolymer and the PBAE due to its kinetics and orthogonality. IEDDA has been intensively and effectively employed in live-cell imaging, chemical biology, biomaterials, material science, and polymer science. First, the pH-responsive hydrophobic PBAE segment was synthesized via Michael addition polymerization of relatively hydrophobic monomers, namely, BDA and AP. At the final stage of the polymerization, the addition of excess BDA yielded acrylate end-capped PBAE, then, it was converted to norbornene end functional PBAE via reacting the terminal acrylates with amino norbornene (Scheme 1A). The molar mass of the PBAE diacrylate was determined by GPC and NMR as M_n,GPC: 7300 g/mol and M_n,NMR: 1830 g/mol. End-group transformation from acrylate to norbornene was confirmed by 1H NMR spectroscopy. As seen from the NMR spectrum of PBAE diacrylate (Figure S1), the signals around 4.10 to 3.60 ppm were characteristic of protons of methylene groups neighboring oxygen atoms. The peaks belonging to protons of methylene groups adjacent to nitrogen and carbonyls appeared at 2.45 and 2.80 ppm, respectively. The peaks between 1.29 and 1.77 ppm were attributed to the alphatic protons of the side chains. The most specific peaks observed at 5.84, 6.11, and 6.40 ppm were ascribed to terminal acrylate protons. Those peaks due to the acrylate functionality disappeared after the Michael addition reaction of amino norbornene with the acrylates, while new peaks of olefin protons of norbornene moieties appeared at 5.96–6.25 ppm with their distinctive shape (Figure S2). The structures of the PBAEs were further confirmed by Fourier transform infrared (FTIR) spectra as shown in Figure S3. The broad bands centered at 3434 cm⁻¹ were attributed to the stretching of O–H groups, and C–H stretching bands were observed at 2930 and 2860 cm⁻¹. Strong bands at 1725 and 1170 cm⁻¹ belonging to C=O and C–O, respectively, supported the PBAE structure. Furthermore, the small band at 1638 cm⁻¹ was considered to be due to C=C stretching vibrations of terminal acrylate and norbornene groups.

P(MAG-co-HEMA) was chosen as the hydrophilic segment bearing glucose groups. The copolymer was synthesized via the RAFT polymerization of 2-HEMA and MAG with a molar ratio of [MAG]:[HEMA]:[CTA]:[AIBN] = 12:12:1:0.25 (Scheme 1B). The molecular mass and polydispersity index were determined by aqueous GPC as M_n,GPC: 10,950 g/mol and M_w,M_GPC: 1,02, respectively. The molecular mass determined by GPC was considerably different than the theoretical value (3900 g/mol). A similar behavior, the higher molecular masses by GPC than theoretical values, was observed by the others. This difference can be related to conformational states of glycopolymer coils or the lower chain transfer coefficient in the polymerization. The chemical structure of P(MAG-co-HEMA) was analyzed with 1H NMR spectroscopy (Figure S5). The most typical proton signals of comonomers, MAG and HEMA, were observed at 5.04 and 3.99 ppm, respectively, which were attributed to the anemic proton signals of the sugar molecules and (–O–CH₂–CH₂–OH) signals of HEMA moieties. After the conjugation of the polymer with amino tetrazene (Tz-NH₂), aromatic proton signals of the tetrazene groups appeared at 7.66 and 7.92 ppm. Furthermore, the appearance of new bands (1438, 1406, and 952 cm⁻¹) attributed to tetrazene moieties in the FTIR spectrum; the typical pink color of the polymer and an absorbance band centered at 538 nm in the UV–vis spectrum of the polymer (Figure 1, spectrum at t = 0 h) supported the incorporation of the tetrizene functionalities on the polymer. The tetrizene functional polymer was then utilized in the fabrication of P(MAG-co-HEMA)-b-PBAE via the tetrizene mediated IEDDA click reaction (Scheme 1C). The reaction was performed by the addition of P(MAG-co-HEMA)-Tz (in...
was observed at 3413, 2930, and 1170 and 1020 cm⁻¹, and confirmed by FTIR and NMR spectroscopy. The stretching band of O−H, C−H, and C−O were observed at 3413, 2930, and 1170 and 1020 cm⁻¹, respectively, in all spectra (Figure 2). Specifically, a sharp stretching band of ester carbonyls of NB-PBAE-NB appeared at 1717 cm⁻¹; while, the spectrum of P(MAG-co-HEMA) contained two carbonyl bands at 1717 and 1632 cm⁻¹ ascribed to the ester and the amide linkages, correspondingly. As compared to that of the precursors, the ester carbonyl band (1717 cm⁻¹) became stronger in the spectrum of the block copolymer, P(MAG-co-HEMA)-b-PBAE. In addition, the appearance of the characteristic peaks of both segments, shift of the aromatic proton peaks of the tetrazine (7.66 and 7.92 ppm), and norbornene peaks (5.96–6.25 ppm) implied the block copolymer formation (Figures 3 and S8).

For further insight, molecular masses of the polymers were analyzed with aqueous GPC. As shown in Figure S9, P(MAG-co-HEMA)-b-PBAE had almost a unimodal GPC trace corresponding to $M_n = 10,950$ g/mol with a low polydispersity index ($M_w/M_n = 1.02$). After the click reaction, the maxima in both the RI signal and light scattering signal were shifted to higher molecular mass of 36,180 g/mol ($M_w/M_n = 1.44$). The increase in molecular mass was higher than the expected one probably due to the incorporation of a segment with a completely different nature. This result supported the formation of the block copolymer.

**pH-Sensitive Behavior of the Polymers.** To confirm the pH sensitivity of the PBAE and the block copolymer [P(MAG-co-HEMA)-b-PBAE], acid—base titration was performed with simultaneous pH and OD measurements. Before titration, both polymers were dispersed in distilled water resulting in a turbid mixture. When the pH values of the mixtures were adjusted to be around 3 by addition of the acid, the solutions became clear due to the hydrophobic/hydrophilic transition in the PBAE segment. The amine groups on the polymers were protonated; thus, the hydrophobic PBAE became hydrophilic and soluble in aqueous solution. These clear solutions were titrated by the addition of small aliquots of NaOH solution (0.1 M). Figure 4 shows both the titration curves (left) and the change in OD against pH during the titration. First, pH changed rapidly with the addition of NaOH (pH 3–6) in the titration curves (Figure 4, left). Then, change in pH slowed down in the range 6.38–7.07 in which tertiary amine groups of PBAE chain were deprotonated gradually. The $\rho_{K_b}$ values of the NB-PBAE-NB and P(MAG-co-HEMA)-b-PBAE were calculated by the determination of inflection point in the derivative of the titration curves as 6.74 and 6.75, respectively. The OD curves (Figure 4, right) supported the protonated/deprotonated transition of the PBAE segments. At acidic pH below $pK_a$, ODs were low since the PBAE segment was protonated and fully soluble; while, the PBAE segments were deprotonated above the $pK_a$ and became insoluble leading to higher turbidity. As a result, P(MAG-co-HEMA)-b-PBAE may form a stable micelle at a physiological pH of 7.4 and exhibit a pH-sensitive hydrophobic/hydrophilic transition in the tumor microenvironment around pH 5.5. The micelles obtained from P(MAG-co-HEMA)-b-PBAE above pH of 7 can be broken gradually around pH 5.5 and release the encapsulated hydrophobic drugs (i.e., DOX). Therefore, such pH-sensitive block copolymers with the PBAE segment are good candidates for anticancer drug carriers.

**Preparation and Characterization of the Micelles.** The pH-sensitive amphiphilic block copolymer P(MAG-co-HEMA)-b-PBAE was utilized to form core–shell self-assembled micelles as the DOX carrier with cancer cell targeting potential. First, the CMC of the amphiphilic polymer with or without DOX was estimated by plotting count rate (kcps) as a function of concentration on a DLS device. The scattering intensities detected for P(MAG-co-HEMA)-b-PBAE concentrations below CMC were constant corresponding to that of deionized water. The CMC of the blank and drug-loaded micelles was estimated as 0.085 mg/mL and 0.0183 mg/mL, respectively, from the intersections of the upper and lower linear trend lines in the plots (Figure 5).
Figure 3. $^1$H NMR spectra of NB-PBAE-NB (A), P(MAG-co-HEMA)-Tz (B), and P(MAG-co-HEMA)-b-PBAE (C) (see Figures S2, S6 and S8 in the Supporting Information for peak assignments).

Figure 4. Titration curves (left) and pH-dependent absorbance (right) of NB-PBAE-NB (A) and P(MAG-co-HEMA)-b-PBAE (B).

Figure 5. CMC estimation for P(MAG-co-HEMA)-b-PBAE with (a) or without (b) DOX by plotting the count rate (kcps) as a function of concentration on a DLS device.
Then, both the blank and the DOX-loaded micelles were prepared by a modified dialysis method. Briefly, the block copolymer or the block copolymer/DOX hydrochloride was dissolved in a minimal amount of DMSO (~300 μL) and dispersed in distilled water. After adjusting the pH to 3, the mixture turned into a clear homogeneous solution, since the PBAE segment was protonated and whole polymer became soluble at low pH values (below \( pK_b \)). Subsequently, the slow addition of dilute NaOH solution induced the protonated/deprotonated or hydrophilic/hydrophobic transition of PBAE at pH higher than \( pK_b \) (6.75) resulting in self-assembly of the polymers into micellar structures (Figure 6b) with a diameter of 179 nm (blank) and 174 nm (DOX-loaded) (Figure 6a). The STEM image (Figure 6c) supported the formation of drug-loaded micelles with a size of 60.3 nm (±8.4 nm) (dried).

The reverse transition (deprotonated/protonated) was observed through hydrodynamic diameter (\( d_{\text{micelle}} \)) measurements on DLS at different pH as shown in Figure 6a. The hydrodynamic diameter increased dramatically when pH decreased, since the micelles were swollen and then broken. Moreover, zeta potential (\( \zeta \)) measurements above and below \( pK_b \) supported this transition as shown in Figure 6d. Around physiological pH (pH 7.4), the zeta potential of the polymeric micelles showed very low positive charge (+2.14 mV), and it was negative under basic conditions such as −13.4 mV at pH 8.5. In contrast, under acidic conditions, the zeta potentials were sharply increased taking the values of +20.8−+27.6 mV in the pH range of 3.0−5.9, because the amine residues of the PBAE segment were fully protonated yielding positively charged quaternary amine residues. The micelles showed a relatively low zeta potential of +16.7 mV at pH 6.1, which was close to \( pK_b \) (6.75), due to partial protonation of the tertiary amines.

The DOX content of the lyophilized micelle was determined by using a calibration curve established with absorbance values of DOX solutions of various concentrations at the same wavelength (483 nm). The amount of DOX encapsulated by 70 mg of micelles was determined as 6.2 mg; as a result, DLC (%) and DLE (%) were found to be 9 and 89%, respectively.

In Vitro Release of DOX from Polymeric Micelles. As polymeric micelles exhibited a pH-responsive property, the in vitro drug release performance of the micelles was tested at physiological (PBS, 0.01 M, pH 7.4) and acidic pH (PBS, 0.01 M, pH 5.30) as shown in Figure 7. It can be found obviously
that the DOX release rates from the particles were significantly changed at different pH values. The micelles at pH 5.30 had a higher release rate and amount of DOX compared to those at pH 7.40. The improved release at lower pH was attributed to disassembly of the micelles due to the hydrophobic/hydrophilic transition of the PBAE segment.

**Cell Viability Assay.** The optimum efficiency of the DOX-loaded micelles was obtained in 24 h of incubation. In noncancerous HUVEC cells, DOX treatment in all tested concentrations killed the cells whereas micelles with or without DOX were not toxic for cells. However, DOX-loaded micelles (EK255) significantly reduced cell viability whereas micelles without DOX (EK257) did not significantly affect U87-MG cell viability (Figure 8). The results indicated that DOX encapsulation specifically targeted the cancer cells and reduced the cell viability within 24 h of incubations whereas noncancerous cells were not affected by the micelle treatment.

Polymeric micelle encapsulation increased the specific activity of DOX induced cytotoxicity. While polymeric micelles are not cytotoxic to both cancer and noncancer cells, when they are loaded with an anticancer drug, they specifically targeted cancer cells. Previous studies with similar approaches including micelle and DOX treatments also reported reduced cell viability on several cancer cells HeLa, HepG2[^82,85] and MCF-7[^82] cells. However, in our study, we reported that the toxic effect of DOX encapsulated into polymeric micelles was similar to only DOX treatment in U87-MG cells with better efficiency after 24-hour incubation.

In addition, it was observed that the release of DOX from micelles provided higher toxicity, especially at a concentration below 5 μg/mL. It implies that, besides changes in pH[^82,85] the drug concentration in the micelle is also effective in releasing hydrophobic drugs (like DOX) in U87-MG cells.

**Cellular Uptake Assay.** Cellular uptake of DOX was assessed by microscopic evaluation of cells when treated with DOX and the micelles. Cellular uptake of free DOX was determined around 100%, while the uptake was approximately 98% when the cells were treated with DOX-loaded micelles (EK-255) for 4 h (Figure 9). The results showed that the micelles with DOX can successfully release the DOX content within 4 h and the micelles without DOX (EK257) did not induce any cell death within this period. Therefore, we propose that the micellar structure developed is a successful targeted drug delivery system with no cellular toxicity.

Annexin V Staining Assay. Annexin V staining was used to assess the extent of cell death with the percentage of early, late apoptosis, and death cells. Untreated U87-MG cells showed no cell death or apoptosis while 2 h of DOX treated cells showed 98% of dead cells. The cells treated with DOX-loaded micelle (EK255) for 2 h showed 39% of cell death, and those treated for 4 h of treatment caused 97% of cells to die which is consistent with free DOX treatment. However, neither 2 h nor 4 h of empty micelle (EK257) treatment caused significant cell death (Figure 10). The results indicated that drug release from the DOX-loaded micelles occurs within 4 h of treatment. DOX caused apoptosis was not detected in both 2 and 4 h of treatments. Hence, we can speculate that the effect of DOX is immediate and occurs in less than 2 h.

**CONCLUSIONS**

In conclusion, a micellar drug carrier was fabricated from P(MAG-co-HEMA)-b-PBAE to realize pH-responsive release and potentially active targeting cancer cells. The P(MAG-co-HEMA) block was chosen to be hydrophilic and a cancer cell targeting block with glucose groups, while PBAE was chosen as a pH-sensitive hydrophobic and degradable segment. The amphiphilic polymer formed a micellar structure above pK_{b1} (>6.75) and released the hydrophobic model drug DOX below pK_{b2} (<6.75). Drug delivery potential was evaluated by cell
viability assays for both the noncancerous HUVEC cell line and glioblastoma cell line U87-MG. While encapsulated DOX into the polymeric micelles was not toxic in noncancerous HUVEC cells, being toxic only to cancer cells indicates that it is a potential specific cell targeting strategy in the treatment of cancer. Our results are promising for future in vivo studies.

**Figure 10.** Annexin V analysis by flow cytometry. Cell death effects of free DOX, DOX-loaded micelle (EK-255), and empty micelle (EK-257) in U87-MG cells.

### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.biomac.2c01076](https://pubs.acs.org/doi/10.1021/acs.biomac.2c01076).

Reaction schemes, NMR spectra, FTIR spectra, and GPC chromatograms (DOCX)
**AUTHOR INFORMATION**

**Corresponding Author**
Muhammet U. Kahveci — Faculty of Science and Letters, Department of Chemistry, Istanbul Technical University, 34467 Istanbul, Turkey; orcid.org/0000-0001-7287-6181; Email: kahvecimuh@itu.edu.tr

Serap Derman — Faculty of Chemical and Metallurgical Engineering, Department of Bioengineering, Yildiz Technical University, 34210 Istanbul, Turkey; orcid.org/0000-0002-6662-6642; Email: serapcar5@gmail.com

**Authors**
Elif L. Sahkulubey Kahveci — Faculty of Chemical and Metallurgical Engineering, Department of Bioengineering, Yildiz Technical University, 34210 Istanbul, Turkey; orcid.org/0000-0002-2151-3994

Asuman Celebi — Department of Medical Biology, School of Medicine, Baskesehr University, 34734 Istanbul, Turkey

Timucin Avsar — Department of Medical Biology, School of Medicine, Baskesehr University, 34734 Istanbul, Turkey

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.biomac.2c01076

**Author Contributions**
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

**Notes**
The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**
The authors thank the Center for Life Sciences and Technologies at Bogazici University for help in acquiring the STEM images. M.U.K. thanks the Turkish Academy of Sciences for financial support under Outstanding Young Scientists Award Program (TUBA-GEIP). E.L.S.K. is grateful to the Council of Higher Education of Turkey (YOK 100/2000 PhD Scholarship) and to TUBITAK (2211-C PhD Scholarship) for financial support.

**REFERENCES**

(1) Bae, Y. H.; Park, K. Advanced drug delivery 2020 and beyond: Perspectives on the future. *Adv. Drug Deliv. Rev.* 2020, 158, 4–16.
(2) Mitchell, M. J.; Billingsley, M. M.; Haley, R. M.; Wechsler, M. E.; Peppas, N. A.; Langer, R. Engineering precision nanoparticles for drug delivery. *Nat. Rev. Drug Discovery* 2021, 20, 101–124.
(3) Blanco, E.; Shen, H.; Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat. Biotechnol.* 2015, 33, 941–951.
(4) Kamaly, N.; Xiao, Z.; Valencia, P. M.; Radovic-Moreno, A. F.; Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. *Chem. Soc. Rev.* 2012, 41, 2971–3010.
(5) Roy, D.; Cambre, J. N.; Sumerlin, B. S. Future perspectives and recent advances in stimuli-responsive materials. *Prog. Polym. Sci.* 2010, 35, 278–301.
(6) Stuart, M. A. C.; Huck, W. T. S.; Genzer, J.; Müller, M.; Ober, C.; Stamm, M.; Sukhorukov, G. B.; Szleifer, I.; Tsukruk, V. V.; Urban, M.; Winnik, F.; Zauscher, S.; Luzinov, I.; Minko, S. Emerging applications of stimuli-responsive polymer materials. *Nat. Mater.* 2010, 9, 101–113.
(7) Blakney, A. K.; Zhu, Y.; McKay, P. F.; Bouton, C. R.; Yeow, J.; Tang, J.; Hu, K.; Samnuan, K.; Grigsby, C. L.; Shattock, R. J.; Stevens, M. M. Big Is Beautiful: Enhanced sRNA Delivery and Immunogeneity of a Higher Molecular Weight, Bioreducible, Cationic Polymer. *ACS Nano* 2020, 14, 5711–5727.
(8) Corbet, C.; Feron, O. Tumour acidosis: from the passenger to the driver’s seat. *Nat. Rev. Cancer* 2017, 17, 577–593.
(9) Estrella, V.; Chen, T.; Lloyd, M.; Wojtkowiak, J.; Cornnell, H. H.; Ibrahim-Hashim, A.; Bailey, K.; Balagurunathan, Y.; Rothberg, J. M.; Sloane, B. F.; Johnson, J.; Gatenby, R. A.; Gillies, R. J. Acidity Generated by the Tumor Microenvironment Drives Local Invasion. *Cancer Res.* 2013, 73, 1524–1535.
(10) van Sluis, R.; Bhujwalla, Z. M.; Raghunand, N.; Ballesteros, P.; Alvarez, J.; Cerdán, S.; Galons, J.-P.; Gillies, R. J. In vivo imaging of extracellular pH using 1H MRSI. *Magn. Reson. Med.* 1999, 41, 743–750.
(11) Liu, J.; Huang, Y.; Kumar, A.; Tan, A.; Jin, S.; Mozhii, A.; Liang, X.-J. pH-Sensitive nano-systems for drug delivery in cancer therapy. *Biomacromolecules* 2014, 32, 693–710.
(12) Lee, E. S.; Oh, K. T.; Kim, D.; Yoon, Y. S.; Bae, Y. H. Tumor pH-responsive flower-like micelles of poly(l-lactic acid)-b-polyethylene glycol-b-poly(l-histidine). *J. Controlled Release* 2007, 123, 19–26.
(13) Lee, E. S.; Gao, Z. G.; Bae, Y. H. Recent progress in tumor pH targeting nanotechnology. *J. Controlled Release* 2008, 132, 164–170.
(14) Li, J. H.; Zhang, X. Q.; Zhao, M. Y.; Wu, L. H.; Luo, K.; Pu, Y. J.; He, B. Tumor-pH-Sensitive PLLA-Based Microsphere with Acid Cleavable Acetal Bonds on the Backbone for Efficient Localized Chemotherapy. *Biomacromolecules* 2018, 19, 3140–3148.
(15) Wei, P.; Gangapurwala, G.; Pretzel, D.; Leisike, M. N.; Wang, L. M.; Hoeppenner, S.; Schubert, S.; Brendel, J. C.; Schubert, U. S. Smart pH-Sensitive Nanogels for Controlled Release in an Acidic Environment. *Biomacromolecules* 2019, 20, 130–140.
(16) Ulbrich, K.; Subu, V. Polymeric anticancer drugs with pH-controlled activation. *Adv. Drug Deliv. Rev.* 2004, 56, 1023–1050.
(17) Prabaharan, M.; Grailer, J. J.; Pilla, S.; Steeber, D. A.; Gong, S. Q. Amphiphilic multi-arm-block polymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor targeted drug delivery. *Biomaterials* 2009, 30, 5757–5766.
(18) Du, J. Z.; Du, X. J.; Mao, C. Q.; Wang, J. Tailor-Made Dual pH-Sensitive Polymer-Doxorubicin Nanoparticles for Efficient Anticancer Drug Delivery. *J. Am. Chem. Soc.* 2011, 133, 17560–17563.
(19) Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly(ethylene oxide)-modified poly(betamino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. *J. Mol. Pharmaceutics* 2005, 2, 357–366.
(20) Song, W. T.; Tang, Z. H.; Li, M. Q.; Lv, S. X.; Yu, H. Y.; Ma, L. L.; Zhuang, X. L.; Huang, Y. B.; Chen, X. S. Tunable pH-Sensitive Poly[betamino ester]s Synthesized from Primary Amines and Diacrylates for Intracellular Drug Delivery. *Macromol. Biosci.* 2012, 12, 1375–1383.
(21) Jon, S.; Anderson, D. G.; Langer, R. Degradeable Poly(aminol alcohol esters) As Potential DNA Vectors with Low Cytotoxicity. *Biomacromolecules* 2003, 4, 1759–1762.
(22) Akinc, A.; Anderson, D. G.; Lynn, D. M.; Langer, R. Synthesis of Poly(betamino ester)s Optimized for Highly Effective Gene Delivery. *Bioconjugate Chem.* 2003, 14, 979–988.
(23) Lynn, D. M.; Langer, R. Degradable Poly(betamino esters): Synthesis, Characterization, and Self-Assembly with Plasmid DNA. *J. Am. Chem. Soc.* 2000, 122, 10761–10768.
(24) Min, K. H.; Kim, J.-H.; Bae, S. M.; Shin, H.; Kim, M. S.; Park, S.; Lee, H.; Park, R.-W.; Kim, I.-S.; Kim, K.; Kwon, I. C.; Jeong, S. Y.; Lee, D. S. Tumor acidic pH-responsive MPEG-poly(betamino ester) polymeric micelles for cancer targeting therapy. *J. Controlled Release* 2010, 144, 259–266.
(25) Ko, J.; Park, K.; Kim, Y.-S.; Kim, M. S.; Han, J. K.; Kim, K.; Park, R.-W.; Kim, I.-S.; Song, H. K.; Lee, D. S.; Kwon, I. C. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(betamino ester) block copolymer micelles for cancer therapy. *J. Controlled Release* 2007, 123, 109–115.
(26) Zhang, C. Y.; Yang, Y. Q.; Huang, T. X.; Zhao, B.; Guo, X. D.; Wang, J. F.; Zhang, L. J. Self-assembled pH-responsive MPEG-b...
(PLA-co-PAE) block copolymer micelles for anticancer drug delivery. *Biomaterials* 2012, 33, 6273–6283.

(27) Potineni, A.; Lynn, D. M.; Langer, R.; Amiji, M. M. Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. *J. Controlled Release* 2003, 86, 223–234.

(28) Huynh, D. P.; Nguyen, M. K.; Pi, B. S.; Kim, M. S.; Chae, S. Y.; Lee, K. C.; Kim, B. S.; Kim, S. W.; Lee, D. S. Functionalized injectable hydrogels for controlled insulin delivery. *Biomaterials* 2008, 29, 2527–2534.

(29) Bingol, B.; Altuncu, S.; Duman, F. D.; Ak, A.; Gulyuz, U.; Acar, H. Y.; Okay, O.; Avci, D. One-Step Injectable and Bioreducible Poly(β-Amino Ester) Hydrogels as Controlled Drug Delivery Platforms. *ACS Appl. Polym. Mater.* 2019, 1, 1724–1734.

(30) Lu, X.; Yang, X.; Meng, Y.; Li, S. Z. Temperature and pH dually-responsive poly(β-amino ester) nanoparticles for drug delivery. *Chin. J. Polym. Sci.* 2017, 35, 534–546.

(31) Zhou, M.; Zhang, X.; Xie, J.; Qi, R.; Lu, H.; Leporatti, S.; Chen, J.; Hu, Y. pH-Sensitive Poly(β-amino ester) Nanocarriers Facilitate the Inhibition of Drug Resistance in Breast Cancer Cells. *Nanomaterials* 2018, 8, 952.

(32) Zhang, R.; Wang, S.-B.; Wu, W.-G.; Kankala, R. K.; Chen, A.-Z.; Liu, Y.-G.; Fan, J.-Q. Co-delivery of doxorubicin and AS1411 aptamer by poly(ethylene glycol)-poly(β-amino esters) polymeric micelles for targeted cancer therapy. *J. Nanopart. Res.* 2017, 19, 224.

(33) Chen, J.; Qiu, X.; Ouyang, J.; Kong, J.; Zhong, W.; Xing, M. M. pH and Reduction Dual-Sensitive Copolymeric Micelles for Intracellular Doxorubicin Delivery. *Biomacromolecules* 2011, 12, 3601–3611.

(34) Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies. *Pharm. Res.* 2005, 22, 2107–2114.

(35) Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly(ethylene oxide)-Modified Poly(β-amino ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs. *1. In Vitro Evaluations*. *Mol. Pharmacol.* 2005, 2, 357–366.

(36) Tang, S.; Yin, Q.; Zhang, Z.; Gu, W.; Chen, L.; Yu, H.; Huang, Y.; Chen, X.; Xu, M.; Li, Y. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials* 2014, 35, 6047–6059.

(37) Zhao, S.; Tan, S.; Guo, Y.; Huang, J.; Chu, M.; Liu, H.; Zhang, Z. pH-Sensitive Docetaxel-Loaded α, β-Tocopheryl Polyelectrolyte Glycol Succinate–Poly(β-amino ester) Copolymer Nanoparticles for Overcoming Multidrug Resistance. *Biomacromolecules* 2013, 14, 2636–2646.

(38) Li, H.; Qian, Z. M. Transferin/transferin receptor-mediated drug delivery. *Med. Res. Rev.* 2002, 22, 225–250.

(39) Sudimack, J.; Lee, R. J. Targeted drug delivery via the folate receptor. *Adv. Drug Delivery Rev.* 2000, 41, 147–162.

(40) Stenzel, M. H. Glycopolymers for Drug Delivery: Opportunities and Challenges. *Macromolecules* 2022, 55, 4867–4890.

(41) Granchi, C.; Fortunato, S.; Minutolo, F. Anticancer agents interacting with membrane glucose transporters. *MedChemComm* 2016, 7, 1716–1729.

(42) Lin, J.; Ma, L.; Zhang, D.; Gao, J.; Jin, Y.; Han, Z.; Lin, D. Tumour biomarkers—Tracking the molecular function and clinical implication. *Cell Proliferation* 2019, 52, No. e12589.

(43)Large, D. E.; Soucy, J. R.; Hebert, J.; Auguste, D. T. Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery. *Adv. Ther.* 2019, 2, No. 1800091.

(44) Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J. Cell. Physiol.* 2005, 202, 654–662.

(45) Jeannot, V.; Mazzaferrro, S.; Lavaud, J.; Vanwonterghem, L.; Henry, M.; Arboleas, M.; Vollaire, J.; Josserand, V.; Coll, J.-L.; Lecommandoux, S.; Schatz, C.; Hurbin, A. Targeting CD44 receptor-
(62) Yang, C.; Xue, Z.; Liu, Y.; Xiao, J.; Chen, J.; Zhang, L.; Guo, J.; Lin, W. Delivery of anticancer drug using pH-sensitive micelles from trilblock copolymer MPEG-b-PBAE-b-PLA. *Mater. Sci. Eng., C* 2018, 84, 254–262.

(63) Kulkarni, B.; Surnar, B.; Jayakannan, M. Dual Functional Nanocarrier for Cellular Imaging and Drug Delivery in Cancer Cells Based on π-Conjugated Core and Biodegradable Polymer Arms. *Biomacromolecules* 2016, 17, 1004–1016.

(64) Pearson, S.; Vitucci, D.; Khine, Y. Y.; Dag, A.; Lu, H.; Save, M.; Billon, L.; Stenzel, M. H. Light-responsive azobenzene-based glycopolymer micelles for targeted drug delivery to melanoma cells. *Eur. Polym. J.* 2015, 69, 616–627.

(65) Surnar, B.; Sharma, K.; Jayakannan, M. Core–shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells. *Nanoscale* 2015, 7, 17964–17979.

(66) Wu, H.; Yang, J.; Sečkut, J.; Devaraj, N. K. In Situ Synthesis of Alkenyl Tetrazines for Highly Fluorogenic Bioorthogonal Live-Cell Imaging Probes. *Angew. Chem., Int. Ed.* 2014, 53, 5805–5809.

(67) Lee, Y.-J.; Karra, Y.; Yang, Y.; Torres-Kolbus, J.; Deiters, A.; Liu, W. R. Genetically encoded unstrained olefins for live cell labeling with tetrazine dyes. *Chem. Commun.* 2014, 50, 13085–13088.

(68) Devaraj, N. K.; Weissleder, R.; Hilderbrand, S. A. Tetrazine-Based Cycloadditions: Application to Pretargeted Live Cell Imaging. *Bioconjugate Chem.* 2008, 19, 2297–2299.

(69) Peterson, V. M.; Castro, C. M.; Lee, H.; Weissleder, R. Orthogonal Amplification of Nanoparticles for Improved Diagnostic Sensing. *ACS Nano* 2012, 6, 3506–3513.

(70) Liong, M.; Fernandez-Suarez, M.; Issadore, D.; Min, C.; Tassa, C.; Reiner, T.; Fortune, S. M.; Toner, M.; Lee, H.; Weissleder, R. Specific Pathogen Detection Using Bioorthogonal Chemistry and Diagnostic Magnetic Resonance. *Bioconjugate Chem.* 2011, 22, 2390–2394.

(71) Oliveira, B. L.; Guo, Z.; Bernardez, G. J. L. Inverse electron demand Diels-Alder reactions in chemical biology. *Chem. Soc. Rev.* 2017, 46, 4989–4950.

(72) Kang, K.; Park, J.; Kim, E. Tetrazine ligation for chemical proteomics. *Proteome Sci.* 2017, 15, 15.

(73) Seo, J.; Park, S. H.; Kim, M. J.; Ju, H. J.; Yin, X. Y.; Min, B. H.; Kim, M. S. Injectable Click-Crosslinked Hyaluronic Acid Depot To Prolong Therapeutic Activity in Articular Joints Affected by Rheumatoid Arthritis. *ACS Appl. Mater. Interfaces* 2019, 11, 24984–24998.

(74) Heo, J. Y.; Noh, J. H.; Park, S. H.; Ji, Y. B.; Ju, H. J.; Kim, D. Y.; Lee, B.; Kim, M. S. An Injectable Click-Crosslinked Hydrogel that Prolongs Dexamethasone Release from Dexamethasone-Loaded Microspheres. *Pharmaceutics* 2019, 11, 438.

(75) Dicker, K. T.; Moore, A. C.; Garabedian, N. T.; Zhang, H.; Scinto, S. L.; Akins, R. E.; Burris, D. L.; Fox, J. M.; Jia, X. Q. Spatial Patterning of Molecular Cues and Vascular Cells in Fully Integrated Hydrogel Channels via Interfacial Bioorthogonal Cross-Linking. *ACS Appl. Mater. Interfaces* 2019, 11, 16402–16411.

(76) Jain, S.; Neumann, K.; Zhang, Y.; Geng, J.; Bradley, M. Tetrazine-Mediated Postpolymerization Modification. *Macromolecules* 2016, 49, 5438–5443.

(77) Çetinkaya, A.; Sadak, A. E.; Ayhan, M. M.; Zorlu, Y.; Kahveci, M. U. Poly-β-amino esters) based potential drug delivery and targeting polymer; an overview and perspectives (review). *Eur. Polym. J.* 2015, 51, 17165–17179.

(78) Lorenzo, M. M.; Decker, C. G.; Kahveci, M. U.; Paluck, S. J.; Maynard, H. D. Homodimeric Protein-Polymer Conjugates via the Tetrazine-trans-Cyclooctene Ligation. *Macromolecules* 2016, 49, 30–37.

(79) Alge, D. L.; Azagarsamy, M. A.; Donohue, D. F.; Anseth, K. S. Synthetically Tractable Click Hydrogels for Three-Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry. *Biomacromolecules* 2013, 14, 949–953.

(80) Kara, S. S.; Ateş, M. Y.; Döveci, G.; Cetinkaya, A.; Kahveci, M. U. Direct synthesis of tetrazine functionalities on polymer backbones. *J. Polym. Sci., Part A: Polym. Chem.* 2019, 57, 673–680.

(81) Spencer, G. H., Jr.; Cross, P. C.; Wiberg, K. B. s-Tetrazine. II. Infrared Spectra. *J. Chem. Phys.* 1961, 35, 1939–1945.

(82) Wen, K.; Zhou, M.; Lu, H.; Bi, Y.; Ruan, L.; Chen, J.; Hu, Y. Near-Infrared/pH Dual-Sensitive Nanocarriers for Enhanced Intracellular Delivery of Doxorubicin. *ACS Biomater. Sci. Eng.* 2018, 4, 4244–4245.

(83) Liu, Y.; Li, Y.; Keskin, D.; Shi, L. Poly(β-Amino Esters): Synthesis, Formulations, and Their Biomedical Applications. *Adv. Healthcare Mater.* 2019, 8, No. 1801359.

(84) Iqbal, S.; Qu, Y.; Dong, Z.; Zhao, J.; Rauf Khan, A.; Rehman, S.; Zhao, Z. Poly(β-amino esters) based potential drug delivery and targeting polymer; an overview and perspectives (review). *Eur. Polym. J.* 2020, 141, No. 110097.

(85) Zhou, X. X.; Jin, L.; Qi, R. Q.; Ma, T. pH-responsive polymeric micelles self-assembled from amphiphilic copolymer modified with lipid used as doxorubicin delivery carriers. *R. Soc. Open Sci.* 2018, 5, No. 171654.